FDA Stakeholder meeting on
#LongCovid today:
@TheCrankyQueer: highlight the need for trans inclusion in trials, including understanding how different labs may present; biomarker nuance
Oved Amitay: need to create a center of excellence to learn from trials in other diseases
Oved: FDA needs to align on decisions across similar fields, needs cross-talk across similar groups
@Dysautonomia: Most even great researchers don't understand autonomic disorders, which happen in up to 2/3 of LC...is there an opportunity to offer autonomic training?
@Dysautonomia: Also, need to make arms in these trials for pre-Covid POTS/MECFS - this helps learn about LC as well (ie does Paxlovid help pre-covid pts) Me: There are over 50 drugs ready to be trialed:
https://docs.google.com/document/d/1JJ9t9wVOXo7UifmTmZQ-J1KXSA_o2MmbAXl8tVGPlA0/edit
Me (Hannah Davis): We have more than enough evidence for some main pathophysiologies of
#LongCovid - including endothelial dysfunction, clotting, reactivated viruses - to be trialing things like anticoagulants, JAK-STAT inhibitors, biphosphonates, learning from existing literature as well
@LisaAMcCorkell: PLRC (
@patientled) is funding a clinical trial on monoclonal antibodies; no PCR tests, no one is testing, insurance not covering them. Want to ask you questions: What work are you doing on LC? What is keeping pharma from being more involved in
#LongCovid?
@IDEpiHeather: launching a treatment survey to see what
#LongCovid patients are trialing, which are working; will be enormously beneficial once thousands of patients fill this out Hilary Martson: also sitting on boards of RECOVER
Rob Califf: this is an issue of net present value; what the market will do; There's a whole bunch of conditions that are not financially attractive right now, and I'm sorry to say that's what you're all [with
#LongCovid] are facing now.
Califf: The question becomes what can be done to make it more financially attractive [to pharma]. It is a fact that for the success of a drug development program, a biomarker is really important
Califf: Repurposed drugs are particularly problematic; are already on the market and won't necessarily bring the same financial return to pharma companies. This is why involvement of the government is important
@exceedhergrasp1 (Jaime Seltzer): important to communicate what subset of the population a drug helps; ie communicating that x drug helps POTS and POTS in
#LongCovid Need to measure the right symptoms; Post-Exertional Malaise is one of most debilitating, needs to be understood and measured
@exceedhergrasp1: seconded my comment on illness duration; early illness is different than those sick at 3+ years BIPOC populations hit hardest/not given access to care - need to make sure they are more than adequately represented in trials, not prevented bc of lack of tests
@dysclinic: no one has confirmation of COVID anymore, trials need to take this into consideration need to include arms of pre-COVID patients with dysautonomia, MECFS pre-authorization is harming patients; preventing therapies getting to patients who would benefit, esp IVIG
@yogafogie: for me LDN has been most helpful, but is not a high reward drug for pharma; for your platform, if you get multiple patients saying a drug like this is helpful, what happens next?
@IDEpiHeather: we haven't done this before but the goal is for aggregate numbers to become adequately convincing; want to generate hypothesis-generating signals for trials. Anecdotal evidence is important but we need this
CURE-ID platform is co-hosted with public-private partnerships to be an openly accessible database
@meighanstone: Single mom, diagnosed with
#LongCovid and MECFS, POTS, asthma from Covid; was president of Malala foundation, now can't get back to work bc can't get repurposed drugs. What pathways can accelerate compassionate use for these drugs?
@meighanstone: Also, is there an internal timeline of what success looks like to FDA (ie by X year we will have approved X drugs for
#LongCovid)?
Rob Califf: patients need to band together and advocate to get drugs approved
Heather: it can be done by others; investigators can submit, so can patient-led research initiatives, can be the sponsor or be the drug sponsor to submit to the agency. But it's extremely challenging; financial incentive not there
In comments,
@TheCrankyQueer: "trials need to be FOR AND WITH CHILDREN — including dosage adjustment, alternative formulations (liquids for kids who can’t swallow pills, etc. We know that HIV treatment lagged. YEARS behind for children."
In summary: some really helpful comments from Heather, but otherwise not nearly enough urgency from the FDA that they understand and are addressing the scope of the problem, including the financial/economic scope